<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>252</serviceExecutionTime><Trial id="185745"><TitleDisplay>Carbon Ion Radiotherapy for Recurrent Gliomas</TitleDisplay><TitleOfficial>Randomized, Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01166308</Identifier><Identifier type="Secondary Organisational">2009-017352-26</Identifier><Identifier type="Organisational Study">CINDERELLA</Identifier><Identifier type="Trial Acronym">CINDERELLA</Identifier></Identifiers><Indications><Indication id="1108">Glioma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Carbon Ion Radiotherapy 36 Gy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fractionated Stereotactic Radiotherapy (FSRT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1079364" type="Company"><TargetEntity id="5034788218" type="organizationId">Universitaetsklinikum Heidelberg</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"/><TargetEntity id="D005910" type="MeSH"/><TargetEntity id="-1503483999" type="omicsDisease"/><TargetEntity id="680" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1079364">University Hospital Heidelberg</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>56</PatientCountEnrollment><DateStart>2010-12-31T00:00:00Z</DateStart><DateEnd type="actual">2016-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:44:21Z</DateChangeLast><DateAdded>2014-05-09T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Unifocal, supratentorial recurrent glioma&lt;/li&gt;&lt;li&gt;Contrast enhancement on T1-weighted MRI and/or Amino-Acid-PET-positive high-grade tumor areas&lt;/li&gt;&lt;li&gt;Indication re-irradiation&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;Karnofsky Performance Score &gt;/= 60&lt;/li&gt;&lt;li&gt;For women with childbearing potential, (and men) adequate contraception&lt;/li&gt;&lt;li&gt;Ability of subject to understand character and individual consequences of the clinical trial&lt;/li&gt;&lt;li&gt;Written informed consent (must be available before enrolment in the trial)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Multifocal Glioma or Gliomatosis cerebri&lt;/li&gt;&lt;li&gt;Refusal of the patients to take part in the study&lt;/li&gt;&lt;li&gt;Previous re-irradiation or prior radiosurgery or prio treatment with interstitial radioactive seeds&lt;/li&gt;&lt;li&gt;Time interval of&amp;lt;/=  6 months after primary radiotherapy&lt;/li&gt;&lt;li&gt;Patients who have not yet recovered from acute toxicities of prior therapies&lt;/li&gt;&lt;li&gt;Known carcinoma&amp;lt;/= 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Participation in another clinical study or observation period of competing trials, respectively&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Phase II: overall survival</Description><Timeframe>At 12 months</Timeframe></Measure><Measure><Description>Phase I: toxicity</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression-free Survival</Description><Timeframe>At 12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study is to evaluate the  efficacy of re-irradiation using carbon ions when  compared      to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in      patients with recurrent gliomas. Within the Phase I Part of the trial, the Recommended Dose      (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme. In the      subsequent randomized Phase II part, the RD will be evaluated in the experimental arm,      compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to receive either carbon Ion Radiotherapy (10 x 3 to 16 x 3 Gy E) or standard treatment as re-Irradiation performed as fractionated stereotactic radiotherapy (FSRT) up to 36 Gy in single doses of 2 Gy. Primary endpoint of the phase I part is toxicity. Primary endpoint of the randomized part II      is survival after re-irradiation at 12 months, secondary endpoint is progression-free      survival.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>University Hospital of Heidelberg, Department of Radiation Oncology</Name><Address1>Heidelberg</Address1><Address3>69120</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9624">Subjects with Brain Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9632">Subjects with Gliomas</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9674">Subjects with Recurrent/Relapsed CNS Tumor</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01166308</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2009-017352-26</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Central nervous system tumor" id="13472"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Central nervous system tumor" id="12981"><Criterion>Subjects with Brain Tumors</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="12989"><Criterion>Subjects with Gliomas</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13052">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13063"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Central nervous system tumor" id="10594"><Criterion>Subjects with Gliomas</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10640"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10668"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10673">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10676"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-07-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-06-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="200391"><TitleDisplay>Nutrition Effects on Fatigue During Tennis Playing</TitleDisplay><TitleOfficial>Effects of Ingestion of Different Sports Drinks on Fatigue During Playing Tennis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01353872</Identifier><Identifier type="Organisational Study">2010-A00724-35</Identifier></Identifiers><Indications><Indication id="829">Fatigue</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Nutrattente/Nutraperf/Nutrarecup</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1026763" type="Company"><TargetEntity id="5035558681" type="organizationId">Universite Blaise Pascal Clermont Ferrand II</TargetEntity></SourceEntity><SourceEntity id="1039580" type="Company"><TargetEntity id="5035542986" type="organizationId">Centre Hospitalier Universitaire de Clermont Ferrand</TargetEntity></SourceEntity><SourceEntity id="1090632" type="Company"><TargetEntity id="5039942094" type="organizationId">Laboratoire Lescuyer SAS</TargetEntity></SourceEntity><SourceEntity id="829" type="ciIndication"><TargetEntity id="10016256" type="MEDDRA"/><TargetEntity id="D005221" type="MeSH"/><TargetEntity id="-961418346" type="omicsDisease"/><TargetEntity id="2620" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1090632">Lescuyer  laboratory</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1026763">Universite Blaise Pascal</Company><Company id="1039580">University Hospital Clermont-Ferrand</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>8</PatientCountEnrollment><DateStart>2010-10-31T00:00:00Z</DateStart><DateEnd type="actual">2011-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-04-10T11:34:50Z</DateChangeLast><DateAdded>2014-06-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Lescuyer Laboratory</Affiliation><Name>Sebastien Peltier, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;About 18 to 35 years (inclusive)&lt;/li&gt;&lt;li&gt;Subject has a stable weight for at least 3 months before the start of the study&lt;/li&gt;&lt;li&gt;Subject able and willing to comply with the protocol and agreeing to give their consent in writing&lt;/li&gt;&lt;li&gt;Subject affiliated with a social security scheme&lt;/li&gt;&lt;li&gt;Subject willing to be included in the national register of volunteers who lend themselves to biomedical research&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Peripheral fatigue measured by surface electromyographic (EMG) signal from the right triceps muscle</Description><Timeframe>Three matches (1.5 days)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of this study was to investigate the effects of ingestion of different      sports drinks (Nutrattente/Nutraperf/Nutrarecup) on fatigue induced by a tennis      tournament simulation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive either placebo or Nutrattente (500 ml)/Nutraperf (500 ml)/Nutrarecup (250 ml).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Sirvent</Name><Address1>Aubiere</Address1><Address3>63177</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01353872</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-05-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="235422"><TitleDisplay>HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men</TitleDisplay><TitleOfficial>A Randomized, Controlled, Open-Label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-Grade Anal Dysplasia Versus Observation Alone in HIV-Positive Men Who Have Sex With Men (MSM)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02503111</Identifier><Identifier type="Organisational Study">HPV-SAVE</Identifier><Identifier type="Trial Acronym">HPV-SAVE</Identifier></Identifiers><Indications><Indication id="1517">Anal dysplasia</Indication><Indication id="2193">Anal tumor</Indication><Indication id="396">Papillomavirus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Infrared Coagulator by Redfield Corporation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>The Hyfrecator 2000 Electrosurgical System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1034426" type="Company"><TargetEntity id="5000817453" type="organizationId">Canadian Institutes of Health Research</TargetEntity></SourceEntity><SourceEntity id="1039734" type="Company"><TargetEntity id="5018076550" type="organizationId">Ontario Hiv Treatment Network</TargetEntity></SourceEntity><SourceEntity id="1059823" type="Company"><TargetEntity id="4295904507" type="organizationId">Merck Sharp &amp; Dohme Corp</TargetEntity></SourceEntity><SourceEntity id="1089437" type="Company"><TargetEntity id="5040272791" type="organizationId">CIHR Canadian HIV Trials Network</TargetEntity></SourceEntity><SourceEntity id="28443" type="Company"><TargetEntity id="4296791312" type="organizationId">University Health Network</TargetEntity></SourceEntity><SourceEntity id="1517" type="ciIndication"><TargetEntity id="K62.82" type="ICD10"/><TargetEntity id="569.44" type="ICD9"/><TargetEntity id="2390" type="siCondition"/></SourceEntity><SourceEntity id="2193" type="ciIndication"><TargetEntity id="C21" type="ICD10"/><TargetEntity id="230.5" type="ICD9"/><TargetEntity id="10061424" type="MEDDRA"/><TargetEntity id="D001005" type="MeSH"/><TargetEntity id="-1699935608" type="omicsDisease"/><TargetEntity id="1335" type="siCondition"/></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"/><TargetEntity id="-774172916" type="omicsDisease"/><TargetEntity id="865" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="28443">The University Health Network</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1034426">Canadian Institutes of Health Research</Company><Company id="1039734">Ontario HIV Treatment Network</Company><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><Company id="1089437">CIHR Canadian HIV Trials Network</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>3000</PatientCountEnrollment><DateStart>2015-11-30T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-06-06T08:30:09Z</DateChangeLast><DateAdded>2015-08-01T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Toronto General Hospital, University Health Network</Affiliation><Name>Irving Salit, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males, aged &gt;/=  18 years at baseline&lt;/li&gt;&lt;li&gt;Identify as a man who has sex with a men (MSM)&lt;/li&gt;&lt;li&gt;Laboratory documentation of HIV-1 infection (enzyme-linked immunoassay and Western Blot)&lt;/li&gt;&lt;li&gt;For those on combination antiretroviral therapy, the participant must be on a stable regimen (ie, virologically suppressed with HIV-1 RNA below the assay's limit of detection for a minimum of 6 months). This is one attempt to minimize confounding from dramatic shifts in viral load and/or CD4 count&lt;/li&gt;&lt;li&gt;An ability to give informed consent&lt;/li&gt;&lt;li&gt;An ability to attend clinic for all study visits&lt;/li&gt;&lt;li&gt;For those continuing to the treatment randomized controlled trial (RCT), AIN-2 or -3 found on biopsy of anal canal lesion(s), and willingness to undergo ablative therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participants having previously undergone anal cancer screening&lt;/li&gt;&lt;li&gt;Prior history of documented treatment of anal dysplasia&lt;/li&gt;&lt;li&gt;Prior receipt of any HPV vaccine&lt;/li&gt;&lt;li&gt;Current or prior history of cancer of the anogenital regions (eg, penile, anal, or rectal)&lt;/li&gt;&lt;li&gt;Inability to consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anal dysplasia treatment on a per-patient basis: histologic resolution of high-grade AIN after treatment completion, with ablative therapies or surveillance alone. Resolution of high-grade AIN will be defined as histologic diagnosis of AIN-1 or normal at the post treatment HRA</Description><Timeframe>Participants will be followed after post-treatment completion, an expected average of 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Acceptance rate of participants recruited into the study: acceptance rates of participant recruitment into the study via an invitational package for anal cancer screening which includes an invitation and educational brochure. Rates of acceptance will account for participants who positively respond to the invitational letter and reminder</Description><Timeframe>Participants will be followed  after recruitment into the study, upto four years</Timeframe></Measure><Measure><Description>Number of participants with adverse events: number of participants assessed on safety, tolerability and acceptability of the different intervention arms and the different treatments in the ablative therapies arms. Evaluation of adverse events and questionnaire-assessed acceptability by intervention arms and ablative treatment type</Description><Timeframe>Participants will be followed after post-treatment completion, an expected average of 36 months</Timeframe></Measure><Measure><Description>Recurrence rates of high-grade AIN: recurrence rates of high-grade AIN following ablative therapy on a per lesion basis</Description><Timeframe>Participants will be followed after post-treatment completion, an expected average of 36 months</Timeframe></Measure><Measure><Description>Resolution of high-grade AIN at 3 and 6 months on a per-lesion basis: resolution of high-grade AIN after treatment on a per-lesion basis. Histologic resolution of high-grade AIN after treatment completion, with ablative therapies or surveillance alone. Resolution of high-grade AIN will be defined as histologic diagnosis of AIN-1 or normal at the post treatment HRA</Description><Timeframe>Participants will be followed after post-treatment completion, an expected average of 6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to examine the efficacy, safety, and tolerability of ablative therapies for high-grade anal dysplasia versus observation alone in a cohort of  HIV-positive men who have sex with men (MSM).&lt;/para&gt;&lt;para&gt;Primary objectives:  &lt;br/&gt;To systematically compare ablative therapy versus      intensive observation alone in outcomes relating to high-grade anal dysplasia.&lt;br/&gt;To      better define evidence-based criteria for anal cancer screening using both anal cytology and      HPV testing through the validation of an algorithm.&lt;/para&gt;&lt;para&gt;Other objectives of the study are:&lt;br/&gt;To assess knowledge of, the attitudes regarding HPV, anal cancer, HPV vaccination, and anal cancer screening to determine the acceptability of vaccination and screening among HIV-positive MSM.&lt;br/&gt;To evaluate the acceptance rate of HIV-positive MSM to an invitation for anal cancer screening which includes an educational brochure in the invitational package.&lt;br/&gt;To optimize decision making about which HIV-positive MSM should be sent for high resolution endoscopy (HRA).&lt;br/&gt;To further elucidate the role played by anal HPV infection as a mucosal immune determinant of HIV transmission and susceptibility in MSM.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study will include two arms:&lt;/para&gt;&lt;para&gt;Arm I: participants with AIN-2 and AIN-3 will be subjected to ablative therapy involving electrocautery (EC). The Hyfrecator 2000 Electrosurgical System will be used for EC therapy. The Hyfrecator 2000 Electrosurgical System will be used for EC therapy. Lesion will be  ablated by  The Hyfrecator 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue will be removed with forceps.&lt;/para&gt;&lt;para&gt;Arm II: participants in this control arm will be subjected to only active surveillance with observation alone; no treatmentwill be given in AIN-2 and -3.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>BC Centre for Disease Control</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V5Z 4R4</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts/></Site><Site><Name>Ottawa Hospital Research Institute</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><Address3>K1Y 4E9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>University Health Network - Toronto General Hospital</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 2C4</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>University of British Columbia</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V6T 1Z4</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment><SubSegments><SubSegment id="7126">Subjects with HIV-1 Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Papillomavirus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10858">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="10859">Subjects with HIV infection</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11905">Others</PatientSegment><SubSegments><SubSegment id="10885">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02503111</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9280"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9284">Assessment of clinical efficacy/response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anal tumor" id="12392"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Anal tumor" id="12393">Assessment of Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Papillomavirus infection" id="17940"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9247">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9280"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9284">Assessment of clinical efficacy/response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anal tumor" id="12368"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anal tumor" id="12377"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anal tumor" id="12392"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Anal tumor" id="12393">Assessment of Efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17901"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17921"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Papillomavirus infection" id="17922">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="31479"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9266">Assessment of acceptability of therapy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="31595"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Papillomavirus infection" id="17926">Assessment of acceptability of therapy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5418">Subjects with HIV-1 infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5317"><Criterion>Subjects with Protocol Specified HIV Viral Load</Criterion></Inclusion><Inclusion disease="HIV infection" id="5344"><Criterion>Subjects on Prior/Concurrent Antiretroviral Therapy</Criterion></Inclusion><Inclusion disease="HIV infection" id="5360"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5374">Recently sexually active subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anal tumor" id="8397"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anal tumor" id="13542">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anal tumor" id="8421"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16634"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="33759"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="16626">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anal tumor" id="34424"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anal tumor" id="8435">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="34441"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5364">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Papillomavirus infection" id="34730"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="16638">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anal tumor" id="34897"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Anal tumor" id="8437">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="34917"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5367">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Papillomavirus infection" id="34999"><Criterion>Subjects on Anti-Microbial Therapy</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="16632">Subjects on Prior/Concurrent Anti-viral Therapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6850"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="HIV infection" id="6967"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6969">Subjects with prior other vaccination</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anal tumor" id="9945"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14623"><Criterion>Subjects with Other Malignancies</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14642"><Criterion>Subjects on Prior/Concurrent Anti-neoplastic Therapy</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14650"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Anal tumor" id="25428"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anal tumor" id="9989">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="25518"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6879">Inability or unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Papillomavirus infection" id="26552"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Papillomavirus infection" id="14640">Subjects with Prior HPV Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-07-10T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-08-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="295202"><TitleDisplay>A retrospective study to evaluate the effect of hydroxyurea on longitudinal pulmonary function testing changes in children with sickle cell anemia</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="303">Sickle cell anemia</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="154" role="Therapeutic effect marker" type="Genomic;Proteomic">Lactate dehydrogenase</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1296" role="Therapeutic effect marker" type="Physiological">Mean corpuscular volume</BiomarkerName><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2029" role="Therapeutic effect marker" type="Physiological">Forced expiratory flow </BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="3054" role="Therapeutic effect marker" type="Cellular">Reticulocytes</BiomarkerName><BiomarkerName id="10157" role="Therapeutic effect marker" type="Structural (imaging)">Lung</BiomarkerName><BiomarkerName id="10684" role="Therapeutic effect marker" type="Cellular">Blood cells</BiomarkerName><BiomarkerName id="18672" role="Therapeutic effect marker" type="Biochemical">Fetal hemoglobin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hydroxyurea</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="16994" type="Company"><TargetEntity id="4298148028" type="organizationId">Hospital for Sick Children</TargetEntity></SourceEntity><SourceEntity id="303" type="ciIndication"><TargetEntity id="10040641" type="MEDDRA"/><TargetEntity id="D000755" type="MeSH"/><TargetEntity id="232" type="ORPHANET"/><TargetEntity id="-2067923175" type="omicsDisease"/><TargetEntity id="994" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="16994">Hospital for Sick Children</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>94</PatientCountEnrollment><PatientCountEvaluable>94</PatientCountEvaluable><DateChangeLast>2017-04-20T16:00:23Z</DateChangeLast><DateAdded>2017-04-21T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects had to be 6 years of age or older at HU initiation&lt;/li&gt;&lt;li&gt;Subjects had  to have undergone PFT before or after the start of HU therapy&lt;/li&gt;&lt;li&gt;Children with sickle cell anemia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Routine blood work including complete blood count, reticulocyte count, and HbF and lactate dehydrogenase levels</Description><Timeframe>At hydroxyurea initiation and on subsequent selected visits</Timeframe></Measure><Measure><Description>Adherence was assessed on the basis of history and laboratory investigations and HU dosing titrated to clinical effect</Description></Measure><Measure><Description>Change in PFT measures over time</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  study was to evaluate the effect of hydroxyurea (HU) on longitudinal pulmonary function testing (PFT) changes in children with sickle cell anemia [&lt;ulink linkType="Reference" linkID="1918687"&gt;1918687&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2017, results were published. After four years of hydroxyurea therapy, hemoglobin increased progressively from 95 to 101 g/L (test for trend, p = 0.02). There were similar increases in HbF concentration and mean corpuscular volume, a decrease in leukocytes and reticulocyte counts was observed. The occurrence of vaso-occlusive events per year decreased (mean, -1.3; p &amp;lt; 0.001). Based on multivariable linear regression adjusting for sex, age, and time from hydroxyurea initiation, there was a relationship between hydroxyurea therapy and PFT parameters including FEV1 (p = 0.02) and FEF25 to 75% (forced expiratory flow, midexpiratory phase) (p = 0.006) [&lt;ulink linkType="Reference" linkID="1918687"&gt;1918687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, results of a subgroup analysis of 56 HbSS patients which was compared with 75 children with SCA (HbSS) not treated with hydroxyurea were published. Patients with at least one PFT before and after hydroxyurea initiation confirmed improved rates of decline in FEV1 (p = 0.06) and FEF25 to 75% (p = 0.06) and in FVC (p = 0.04). The median periods of observation in this group were 3.8 and 2.9 years with a mean of 5.2 measurements before and 4.7 measurements after hydroxyurea initiation, respectively. In HbSS control patients, PFT decline was less pronounced than in hydroxyurea-treated patients before hydroxyurea therapy, likely related to differences in disease severity between groups [&lt;ulink linkType="Reference" linkID="1918687"&gt;1918687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients initiated on hydroxyurea therapy from 2000 to 2011 were evaluated in this study [&lt;ulink linkType="Reference" linkID="1918687"&gt;1918687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-04-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="319222"><TitleDisplay>The study on the relationship between uric acid in fingernail and tissue uric acid deposition</TitleDisplay><TitleOfficial>The study on the relationship between uric acid in fingernail and tissue uric acid deposition</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-ROC-17013271</Identifier></Identifiers><Indications><Indication id="180">Hyperuricemia</Indication></Indications><BiomarkerNames><BiomarkerName id="288" role="Disease marker" type="Biochemical">Uric acid</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1037695" type="Company"><TargetEntity id="4296702079" type="organizationId">Shanghai Jiao Tong University</TargetEntity></SourceEntity><SourceEntity id="1064227" type="Company"><TargetEntity id="5036351964" type="organizationId">Shanghai Sixth People's Hospital</TargetEntity></SourceEntity><SourceEntity id="180" type="ciIndication"><TargetEntity id="10020903" type="MEDDRA"/><TargetEntity id="D033461" type="MeSH"/><TargetEntity id="-1280874117" type="omicsDisease"/><TargetEntity id="740" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037695">Shanghai Jiao Tong University</Company><Company id="1064227">Shanghai Sixth People’s Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2017-11-13T00:00:00Z</DateStart><DateEnd type="estimated">2019-05-31T00:00:00Z</DateEnd><DateChangeLast>2017-11-21T14:18:14Z</DateChangeLast><DateAdded>2017-11-17T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shanghai Jiao Tong University Affiliated Sixth People's Hospital</Affiliation><Email>18930173813@163.com</Email><Name>Haibing Chen</Name><Phone>+86 18930173813</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Control group: according to the level of serum uric acid&amp;lt; 360, 360 to 420 micromol/l, divided into two groups&lt;/li&gt;&lt;li&gt;Hyperuricemia group: according to the level of uric acid 420 to 480 micromol/l, 480 to 540 micromol/l and 540 micromol/l above were divided into three groups&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Nail sites suffering from fungal infection or other diseases that affect the normal state of nails&lt;/li&gt;&lt;li&gt;Any other diseases that can affect the blood uric acid test&lt;/li&gt;&lt;li&gt;Hyperuricemia patients who did not start any uric acid therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum uric acid</Description></Measure><Measure><Description>Uric acid in fingernail</Description></Measure><Measure><Description>Dual energy computed tomography</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Objectives of study: to figure out whether uric acid levels associated with tissue uric acid deposition or not.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients in the case group will be  randomly recruited from outpatients who met the criteria of hyperuricemia and volunteers in the control group voluntarily joined   will be observed to study  the relationship between uric acid in fingernail and tissue uric acid deposition.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</Name><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Gout</Disease><PatientSegments><PatientSegment><PatientSegment id="3745">Hyperuricemic Subjects without Gout</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-ROC-17013271</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Gout" id="3651"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Gout" id="3665"><Endpoint>Assessment of Urate/Uric Acid Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Gout" id="1746"><Criterion>Subjects with Protocol Specified Other Laboratory Assessments</Criterion></Inclusion><Inclusion disease="Gout" id="4329"><Criterion>Hyperuricemic Subjects without Gout</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Gout" id="2550"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Gout" id="2552">Subjects co-morbid with fungal infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gout" id="2557"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Gout" id="2565"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-11-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="328395"><TitleDisplay>Safety and Performance Study of Large Hole Vascular Closure Device FIV</TitleDisplay><TitleOfficial>Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER IV Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03423602</Identifier><Identifier type="Organisational Study">P528-00</Identifier><Identifier type="Trial Acronym">Frontier-IV</Identifier></Identifiers><Indications><Indication id="742">Vascular disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PerQseal large hole closure system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1063511" type="Company"><TargetEntity id="5036352161" type="organizationId">Vivasure Medical Ltd</TargetEntity></SourceEntity><SourceEntity id="742" type="ciIndication"><TargetEntity id="10059245" type="MEDDRA"/><TargetEntity id="D014652" type="MeSH"/><TargetEntity id="-90096021" type="omicsDisease"/><TargetEntity id="1157" type="siCondition"/><TargetEntity id="3754" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>11</NumberOfSites><CompaniesSponsor><Company id="1063511">Vivasure Medical Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>75</PatientCountEnrollment><DateStart>2017-10-12T00:00:00Z</DateStart><DateEnd type="estimated">2018-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T16:40:10Z</DateChangeLast><DateAdded>2018-02-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>chris.martin@vsuremed.com</Email><Name>Dr Chris Martin</Name><Phone>+353 9 395 440</Phone></Contact><Contact type="Scientific contact"><Affiliation>St Fraziskus Hospital, Muenster, Germany</Affiliation><Name>Dr Arne Schwindt</Name></Contact><Contact type="Scientific contact"><Affiliation>Contilia Heart and Vascular centre, Essen, Germany</Affiliation><Name>Dr Christoph Naber</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt; 18 years of age&lt;/li&gt;&lt;li&gt;Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements&lt;/li&gt;&lt;li&gt;Clinically indicated for an endovascular procedure using a common femoral arteriotomy created by a 12 - 20 F sheath&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of&amp;lt; 6 months&lt;/li&gt;&lt;li&gt;Evidence of systemic bacterial or cutaneous infection, including groin infection&lt;/li&gt;&lt;li&gt;Known bleeding diathesis, definite or potential coagulopathy, platelet count&amp;lt; 100,000/microl or patients on long term anticoagulants with an INR &gt; 1.2 at time of procedure or known type II heparin-induced thrombocytopenia&lt;/li&gt;&lt;li&gt;Severe; claudication or peripheral vascular disease (eg, Rutherford category &gt;/= 3  or ABI&amp;lt; 0.5), documented untreated iliac artery diameter stenosis &amp;gt; 50% or previous bypass surgery/stent placement in the common femoral artery of ipsilateral limb&lt;/li&gt;&lt;li&gt;Known allergy to any of the materials used in the PerQseal&lt;/li&gt;&lt;li&gt;Subject has undergone a percutaneous procedure using a non-absorbable vascular closure device (excluding suture mediated) for hemostasis in the ipsilateral target leg&lt;/li&gt;&lt;li&gt;Patients that have undergone a percutaneous procedure in the ipsilateral leg, within the previous 30 days&lt;/li&gt;&lt;li&gt;Patients that have undergone a percutaneous procedure using an absorbable intravascular closure device for haemostasis, in the ipsilateral leg, within the previous 90 days&lt;/li&gt;&lt;li&gt;Evidence of arterial diameter stenosis&amp;gt; 20% or anterior or circumferential calcification within 20 mm proximal or distal to target arteriotomy site based on pre-procedure CT angiography&lt;/li&gt;&lt;li&gt;Females who are pregnant or lactating or in fertile period not taking adequate contraceptives. A pregnancy test may be performed&lt;/li&gt;&lt;li&gt;Patients that have a lower extremity amputation from the ipsilateral or contralateral limb&lt;/li&gt;&lt;li&gt;Arterial access other than common femoral artery obtained for ipsilateral target leg&lt;/li&gt;&lt;li&gt;Subject has a tissue tract expected to be &gt; 10 cm&lt;/li&gt;&lt;li&gt;Use of thrombolytic agents within 24 h prior to or during the endovascular procedure which causes fibrinogen&amp;lt; 100 mg/dl&lt;/li&gt;&lt;li&gt;Significant blood loss/transfusion (defined as requiring transfusion of &gt;/= 4  units of blood products) during index procedure or within 30 days prior to index procedure&lt;/li&gt;&lt;li&gt;Activated clotting time (ACT)&amp;gt; 350 s immediately prior to sheath removal or if ACT measurements are expected to be &amp;gt; 350 s for &gt; 24 h after index procedure&lt;/li&gt;&lt;li&gt;Target puncture site is located in a vascular graft&lt;/li&gt;&lt;li&gt;Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 10 mm proximal of the bifurcation of the superficial femoral/profunda femoris artery&lt;/li&gt;&lt;li&gt;PerQseal Introducer-sheath to ipsilateral femoral artery diameter ratio is &gt;/= 1.05&lt;/li&gt;&lt;li&gt;Subjects with an acute hematoma of any size, arteriovenous fistula or pseudoaneurysm at the target access site; or angiographic evidence of arterial laceration or dissection within the external iliac or femoral artery before the use of the PerQseal closure device&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Major vascular complications (safety): incidence of major vascular access site complications related to the PerQseal closure device (as defined by VARC-2)</Description><Timeframe>Up to 1 month from implantation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Minor vascular complications (safety): incidence of minor vascular access site complications directly related to the PerQseal® closure device (as defined by VARC-2)</Description><Timeframe>Up to 1 month from implantation</Timeframe></Measure><Measure><Description>Study device technical success rate (performance): technical success rate for the PerQseal closure device (percentage of subjects not requiring alternative therapy to achieve hemostasis)</Description><Timeframe>Within 24 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study is a prospective, multicenter, non-randomized study to investigate the      safety and performance of the PerQseal in 75 patients in approximately ten European      investigational sites.&lt;br/&gt;The purpose of this Clinical Investigation Plan (CIP) is to:&lt;br/&gt;Confirm the safety and performance of the PerQseal large hole closure system.&lt;br/&gt;To expand its indications of use to include common femoral arteriotomies created with 12           to 20 F sheaths in patients undergoing endovascular procedures.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will not be blinded prior to, during or post the procedure. All patients      will undergoing an endovascular procedure requiring an arteriotomy created by 12 to 20 F sheaths,      via the common femoral artery will be screened against the inclusion/exclusion criteria. If      the patient meets the requirements of the clinical investigation, patients shall be invited to      participate, provide informed consent and shall subsequently be assigned a patients number. Patients will receive PerQseal closure system.&lt;/para&gt;&lt;para&gt;All patients will have an immediately post procedure, 24 h, 1 and 3 month follow-up      assessment. Safety data from the follow-ups will be assessed by the Data Safety Monitoring      Committee on a continuous basis.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Asklepios Klinik St. Georg Medizinische Abteilung</Name><Address1>Hamburg</Address1><Address3>20099</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Christian Freker, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Tobias Schmidt, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Dimitry Schewel, MD</Name></Contact><Contact type="Facility investigator"><Name>Prof Karl-Heinz Kuck, MD</Name></Contact></Contacts></Site><Site><Name>CardioVasculäres Centrum</Name><Address1>Frankfurt am Main</Address1><Address2>Hesse</Address2><Address3>60389</Address3><CountrySubDivision>Hesse</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Prof Horst Sievert, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Iiona Hofmann, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Kolja Sievert, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Laura Vaskelyte, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Markus Reinartz, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Predrag Matić, MD</Name></Contact></Contacts></Site><Site><Name>Contilia Heart and Vascular centre</Name><Address1>Essen</Address1><Address2>North Rhine-Westphalia</Address2><Address3>45138</Address3><CountrySubDivision>North Rhine-Westphalia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Christoph Naber, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Alexander Wolf, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Thomas Schmitz, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Pieter Ghijselinck, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Esther Vogel, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Sultan Alotaibi, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Ingmar Seifert, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Christoph Jensen, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Regina Eder, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Ioannis Tsilingiris, MD</Name></Contact></Contacts></Site><Site><Name>Kerckhoff Klinik, Bad Nauheim</Name><Address1>Bad Nauheim</Address1><Address2>Hesse</Address2><Address3>61231</Address3><CountrySubDivision>Hesse</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Won-Keun Kim, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Christoph Liebetrau, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Matthias Renker, MD</Name></Contact></Contacts></Site><Site><Name>Medical Faculty of the University of Leipzig</Name><Address1>Leipzig</Address1><Address2>Saxony</Address2><Address3>04109</Address3><CountrySubDivision>Saxony</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Prof Dierk Scheinert, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Andrej Schmidt, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Daniela Branzan, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Holger Staab, MD</Name></Contact></Contacts></Site><Site><Name>St Franziskus Hospital</Name><Address1>Muenster</Address1><Address2>North Rhine-Westphalia</Address2><CountrySubDivision>North Rhine-Westphalia</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Arne Schwindt, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Theodosios Bisdas, MD</Name></Contact></Contacts></Site><Site><Name>The Charité - Universitätsmedizin</Name><Address1>Berlin-Mitte</Address1><Address2>Berlin</Address2><Address3>10117</Address3><CountrySubDivision>Berlin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Michael Laule, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Henryk Dreger, MD</Name></Contact></Contacts></Site><Site><Name>Uniklinik Köln, Herzzentrum</Name><Address1>Köln</Address1><Address2>North Rhine-Westphalia</Address2><Address3>50937</Address3><CountrySubDivision>North Rhine-Westphalia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Prof Tanja Rudolph, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Kai Friedrichs, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Elma Kuhn, MD</Name></Contact><Contact type="Facility investigator"><Name>Prof Volker Rudolph, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Navid Mader, MD</Name></Contact><Contact type="Facility investigator"><Name>Prof Thorsten Wahlers, MD</Name></Contact></Contacts></Site><Site><Name>Universitätsmedizin Mainz</Name><Address1>Mainz</Address1><Address2>Rhineland-Palatinate</Address2><Address3>55131</Address3><CountrySubDivision>Rhineland-Palatinate</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Eberhard Schulz, MD</Name></Contact><Contact type="Facility investigator"><Name>Dr Ralph von Bardeleben, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Ireland"><Sites><Site><Name>Blackrock Clinic</Name><Address1>Blackrock</Address1><Address2>Dublin</Address2><CountrySubDivision>Dublin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Peter Crean, MD</Name></Contact></Contacts></Site><Site><Name>St James Hospital</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Dr Peter Crean, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03423602</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21852"><Endpoint>Assessment of complications</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21936"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21852"><Endpoint>Assessment of complications</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21928"><Endpoint>Assessment of Success</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21931">Device Success</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21936"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21970"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="22031">Hemostasis</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19287"><Criterion>Subjects with PAD Interventions</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19291">Subjects with endovascular intervention</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="34464"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19328">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="34853"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19320">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15939"><Criterion>Subjects with Peripheral Arterial Diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15944">Subjects with intermittent claudication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15950"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16003">Subjects co-morbid with aneurysm</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15960"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15965">Subjects with arteriosus-venous fistula</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15981"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16008"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16019">Subjects with abnormal hematology</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16026">Subjects with history of anticoagulant medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16033"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16042">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16045"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16046">Subjects with history/requiring amputation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16054"><Criterion>Subjects with Inappropriate Vascular/Vessel Anatomy</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16065"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16066">Subjects with history/refuses blood transfusion</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16073">Subjects with limited vascular access</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16075">Subjects with life-threatening disease</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16091">Subjects previously implanted stent at the treatment site</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="24935"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="25354"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16074">Subjects with Poor/Limited Life Expectancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25761"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16095">Pregnant/lactating women</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16109">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-01-31T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-02-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="342513"><TitleDisplay>Retrospective comparison of two endoscopic approaches for esophagectomy in the treatment of esophageal cancer: pneumatic mediastinoscopy versus thoracoscopy combined with laparoscopic resection</TitleDisplay><TitleOfficial>Retrospective comparison of two endoscopic approaches for esophagectomy in the treatment of esophageal cancer: pneumatic mediastinoscopy versus thoracoscopy combined with laparoscopic resection</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800016516</Identifier></Identifiers><Indications><Indication id="1011">Esophagus tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="12521" role="Disease marker" type="Structural (imaging)">Lymph node</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laparoscopy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pneumatic mediastinoscopy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>thoracoscopy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1054418" type="Company"><TargetEntity id="5035550177" type="organizationId">Changzheng Hospital</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"/><TargetEntity id="150" type="ICD9"/><TargetEntity id="10061882" type="MEDDRA"/><TargetEntity id="D004938" type="MeSH"/><TargetEntity id="-1694229607" type="omicsDisease"/><TargetEntity id="598" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1054418">Shanghai Changzheng Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>49</PatientCountEnrollment><DateStart>2016-10-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-10-01T00:00:00Z</DateEnd><DateChangeLast>2018-06-18T04:41:27Z</DateChangeLast><DateAdded>2018-06-12T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Thoracic Surgery, Changzheng Hospital,The Second Military Medical University</Affiliation><Email>jinyuxiang666@163.com</Email><Name>Yuxiang Jin</Name><Phone>+86 15026978693</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Thoracic Surgery, Changzheng Hospital,The Second Military Medical University</Affiliation><Email>xuewei_zhao@smmu.edu.cn</Email><Name>Xuewei Zhao</Name><Phone>+86 021-81885701</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Tumor length was&amp;lt;/= 60 mm, and endoscopy before surgery revealed that lymphadenectasis or distal lymphatic metastasis could be excluded&lt;/li&gt;&lt;li&gt;The patients had no history of thoracic surgery on the affected side, had no pre-surgical adjuvant chemotherapy and radiotherapy, and have esophagectomy and lymph node dissection during surgery. Surgical operations of the two groups were all performed by the same team of surgeons&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who do not meet the inclusion criteria&lt;/li&gt;&lt;li&gt;Patients who are participating in other clinical studies&lt;br/&gt;&lt;br/&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Lymph nodes</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim was to compare two endoscopic approaches for esophagectomy in the treatment of esophageal cancer: pneumatic mediastinoscopy versus thoracoscopy combined with laparoscopic resection.  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would undergo either thoracoscopy or mediastinoscopy, combined with laparoscopy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shanghai Changzheng Hospital</Name><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800016516</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Esophagus tumor" id="12030"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Esophagus tumor" id="7808"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Esophagus tumor" id="9357"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9358">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Esophagus tumor" id="9362">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Esophagus tumor" id="9363">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="9369"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="25494"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9374">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="26433"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="27571"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-06-19T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="345376"><TitleDisplay>Changes in oxygenation of skin and muscles after the use of Functional Bandage in women with Varicose Veins</TitleDisplay><TitleOfficial>Kinesio Taping use in tissue oxygenation in women with Chronic Venous Insufficiency: a randomized clinical trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">RBR-9bhbrp</Identifier><Identifier type="Other">U1111-1196-3682</Identifier><Identifier type="Other">57708416.0.0000.5149 - CAAE</Identifier><Identifier type="Other">1.833.009</Identifier></Identifiers><Indications><Indication id="3216">Venous insufficiency</Indication></Indications><BiomarkerNames><BiomarkerName id="6088" role="Therapeutic effect marker" type="Biochemical">Deoxyhemoglobin</BiomarkerName><BiomarkerName id="6338" role="Therapeutic effect marker" type="Biochemical">Oxyhemoglobins</BiomarkerName><BiomarkerName id="48658" role="Therapeutic effect marker" type="Physiological">Tissue oxygenation</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Kinesio taping tapes</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>exercises</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>exercises</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25676" type="Company"><TargetEntity id="5001180623" type="organizationId">Universidade Federal de Minas Gerais UFMG</TargetEntity></SourceEntity><SourceEntity id="3216" type="ciIndication"><TargetEntity id="10057320" type="MEDDRA"/><TargetEntity id="D014689" type="MeSH"/><TargetEntity id="-1456968197" type="omicsDisease"/><TargetEntity id="1700" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25676">Universidade Federal de Minas Gerais</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2017-03-14T00:00:00Z</DateStart><DateChangeLast>2018-08-01T22:02:14Z</DateChangeLast><DateAdded>2018-07-06T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Universidade Federal de Minas Gerais</Affiliation><Email>danielleufmg@gmail.com</Email><Name>Danielle Aparecida Gomes Pereira</Name><Phone>+55 -031-34094592</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Must be female, be between 30 and 79 years old and present the diagnosis of chronic venous insufficiency (confirmed by Duplex Scan) or classified in stages C1, C2 or C3 of CEAP&lt;/li&gt;&lt;li&gt;To be included in the study the participants may not be on hormone replacement therapy and may not have symptoms of intermittent claudication, lymphedema, diagnosis of thrombosis for&amp;lt; 3 months, heart failure, and no other type of conservative treatment for IVC, or have undergone sclerotherapy or surgery in the past 3 months&lt;/li&gt;&lt;li&gt;In addition, they can not present any contraindication to the use of KT such as open sores, trauma, edema arising from heart or kidney disease, cancer, KT allergy, and pregnancy&lt;/li&gt;&lt;li&gt;All patients must agree to participate in the research by signing the Informed Consent Term&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who present knesio taping allergy or intolerance will be excluded&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Evaluation of the tissue perfusion variables (oxyhemoglobin, deoxyhemoglobin and peripheral saturation) will be done using the equipment that uses near infrared (NIRS), model Portamon System (Artinis, The Netherlands).Measurements of tissue perfusion with NIRS will be done, venous occlusion's maneuver followed by arterial occlusion's maneuver.</Description><Timeframe>Evaluations will be done at the beginning and after 4 weeks of treatment. The first evaluation will take place in 2 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Quality of life through the questionnaire: Medical Outcomes Study -36-Item Short-Form Health Survey (SF-36), this being a multidimensional questionnaire, consisting of 36 items, which aims to assess quality of life. It evaluates the following dimensions: functional capacity (ten items), physical appearance (two items), pain (two items), general health status (five items), vitality (four items), mental health Two items) and emotional (three items)</Description></Measure><Measure><Description>Edema: through the circumference of the leg: the tape measure will be used to measure the calf diameter, before and after intervention, to compare them and to contact if there was inferential alteration of the edema in the lower limbs. It will be performed in the legs, using as reference three measurement sites: just below the lower pole of the patella, just above the malleoles and at the midpoint between these two measurements</Description></Measure><Measure><Description>Symptoms: assessed by visual analogue scale: it is an instrument that allows the simple measurement of the intensity of the pain. It is characterized by the use of a 10 cm line containing, at its ends, phrases like 'absence of pain' and 'unbearable pain'. In the present study, the participants will be asked to mark the intensity of the symptoms in the 10 cm trait, by means of the questioning: 'Mark in this trait the intensity of the sensation that is feeling of heavy, swollen legs, cramps, heat or burning, itching or Tingling. Knowing that the zero (0) is 'absence of symptom' and the 10 'unbearable symptom</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a randomized clinical trial todeterminer the effect of Kinesio Taping use in tissue oxygenation in women with Chronic Venous Insufficiency.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will  be divided into two  groups:&lt;br/&gt;Intervention group: Kinesio taping tapes will be applied with the objective of activating lateral and medial gastrocnemius muscles, using 10 to 15% tension. All applications will be performed by the same professional, being exchanged three times a week, during 4 weeks, totaling 12 attendances. After placement of the tapes, the volunteers will perform a treatment protocol, which consists of stretching the tibial muscululosis for 1 min, activated movement of dorsiflexion and plantar flexion for 2 min, three sets of 10 repetitions of inversion, eversion and circumvention, two series of plantar flexion in the orthostatic position (number of repetitions will be by means of the calculation of 80% of the Heel Rise test), three series of 10 repetitions of step, in both flexion and hip abduction, 10 min of walk, being the heart rate representative of 80 to 90% of the maximum heart rate of the Shuttle Walk test. &lt;br/&gt;Control group: the use of placebo tapes and the same exercises as the intervention group will be done.&lt;br/&gt;A total of 120 volunteers will be required, organized into 40 individuals in each of the three strata (C1, C2, C3) and subdivided equally into the control and intervention groups. However, after collecting the data of 20 individuals a new sample calculation will be performed to confirm the sample size.&lt;/para&gt;&lt;para&gt;Evaluation of the tissue perfusion variables (oxyhemoglobin, deoxyhemoglobin and peripheral saturation) will be done using the equipment that uses near infrared (NIRS), model Portamon System (Artinis, The Netherlands). Evaluations will be done at the beginning and after four weeks of treatment. The first evaluation will take place in two days. Measurements of tissue perfusion with NIRS will be done, venous occlusion's maneuver followed by arterial occlusion's maneuver. In addition to the measurement during treadmill tests, plethysmography movement, Incremental Shuttle Walk Test and Heel-rise test, these in random order. On the second day (between 48 hours and a maximum of one week) NIRS measurements will be done before and after KT placement (intervention and control). During 30 minutes the tissue oxygenation variables will be measured by the NIRS at rest, and then the participants will again perform the movements and plethysmography. In the GC volunteers KT will be placed in the same places, without the necessary positions and tensions. KT tapes should be replaced three times in the week prior to the exercise protocol in both groups. At the end of the four weeks (totaling twelve meetings), the reevaluation will be carried out respecting the randomization of the tests.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10150">Subjects with Chronic Venous Insufficiency</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier>RBR-9bhbrp</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21721"><Endpoint>Assessment of Exercise Treadmill Test</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21724"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21733"><Endpoint>Assessment of Tissue Perfusion Measurements</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21857"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21939"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21954"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21965">Venous occlusion plethysmography</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="44735"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="26275">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="26295">Pain scores</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21893"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21939"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21941"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="44735"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="44784"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="45210"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="45256"><Endpoint>Neurological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19210"><Criterion>Subjects with Venous Insufficiency</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19315"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="34464"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19328">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15939"><Criterion>Subjects with Peripheral Arterial Diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15944">Subjects with intermittent claudication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15950"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15958">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15980"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16033"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16042">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16045"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16065"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="25761"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16095">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25907"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16007">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="27449"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-06-20T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>15.23 Months</EnrollmentPeriod><EnrollmentRate>7.88 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="367326"><TitleDisplay>TEE Image Quality Improvement With Our Devised Probe Cover</TitleDisplay><TitleOfficial>TEE Image Quality Improvement With Our Devised Transesophageal Echocardiography Probe Cover and Its Effect on Surgical Decision Making</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03812185</Identifier><Identifier type="Organisational Study">11958</Identifier></Identifiers><Indications><Indication id="201">Liver disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Liver transplantation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>TEE image after suctioning</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>suctioning orogastric tube attached transesophageal echocardiography (TEE)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>TEE image before suctioning</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="22802" type="Company"><TargetEntity id="4296572243" type="organizationId">Henry Ford Health System</TargetEntity></SourceEntity><SourceEntity id="23945" type="Company"><TargetEntity id="5008535209" type="organizationId">Henry Ford Hospital</TargetEntity></SourceEntity><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"/><TargetEntity id="D008107" type="MeSH"/><TargetEntity id="-35813413" type="omicsDisease"/><TargetEntity id="415" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22802">Henry Ford Health System</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23945">Henry Ford Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>42</PatientCountEnrollment><DateStart>2019-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-14T06:32:32Z</DateChangeLast><DateAdded>2019-01-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Henry Ford Health System</Affiliation><Name>Yoshihisa Morita</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;OLT which had intraoperative TEE&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General contraindication with TEE&lt;/li&gt;&lt;li&gt;Inability to obtain image to measure HVF using TEE&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Image quality assessment before/after suctioning: image quality assessment by Likert scale before/after suctioning, appropriate measuring using images stored before/after suctioning</Description><Timeframe>Intra-operative (10 min estimated for suctioning and acquiring necessary images)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;With using suction tube attached transesophageal echocardiography (TEE) probe cover, investigator will assess its pin-point suction      capacity on image quality and surgical decision making.&lt;br/&gt;For intra-operative TEE used cardiac or transplant cases, investigators will compare TEE image quality before and after suctioning using orogastric tube attached TEE probe cover.&lt;/para&gt;&lt;para&gt;The study aims to:&lt;br/&gt;Assess TEE image quality before and after pin-point suctioning with  newly      designed TEE probe. Investigator hypothesize that decreasing stomach air between the TEE probe      transducer and tissue wall by pin-point suction with  newly designed TEE probe will reduce      ultrasound reflection and lead to better image qualiy.&lt;br/&gt;Evaluate the clinical utility of  newly designed TEE probe cover. Investigator hypothesize       newly designed TEE probe cover will facilitate decision-making for both anesthesiologists      and surgeons and it will not increase the occurrence of TEE probe related trauma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study population will be elective      cardiac cases and liver transplant cases at Henry Ford Hospital. For intra-operative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. Patients will be randomized into two arms in which TEE image before suctioning will be done in one arm and TEE image after suctioning          will be done in the other arm.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>HFHS</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3>48202</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>kjones1@hfhs.org</Email><Name>Kelly Jones</Name><Phone>313-874-4420</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Liver transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="634">Liver Transplant Recipients</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03812185</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Liver transplantation" id="4847"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Liver transplantation" id="44083"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Liver transplantation" id="2517"><Criterion>Liver Transplant Recipients</Criterion><SubCriteria><SubCriterion disease="Liver transplantation" id="2518">Orthotopic liver transplant recipients</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Liver transplantation" id="2637"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Liver transplantation" id="3780"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-01-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="removed"><Date>2019-05-15T00:00:00Z</Date><Reason id="321">Trial Biomarker Removed</Reason></Change></ChangeHistory></Trial><Trial id="381792"><TitleDisplay>Clinical study to evaluate the interchangeability of cefuroxime, in healthy volunteers, both sexes, from the medicine Zinnat of GlaxoSmithkline Mexico, versus cefuroxime manufactured by Weser Pharma, in oral suspension at a dose of 250 mg in 5 ml</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">BQ-2018-33-CFR-E/A</Identifier></Identifiers><Indications><Indication id="746">Infectious disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cefuroxime (Weser Pharma)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>cefuroxime (antibacterial), GlaxoSmithKline</Name><Drug id="44368">cefuroxime (antibacterial), GlaxoSmithKline</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1122475" type="Company"><TargetEntity id="5050898231" type="organizationId">Unidad Clinica Bioequivalencia S de RL de CV</TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1122475">Unidad Clínica Bioequivalencia S. De R.L. De C.V.</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="66">Antibiotic</Technology><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term></TermsEndpoint><DateChangeLast>2019-05-29T04:22:39Z</DateChangeLast><DateAdded>2019-05-30T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy volunteers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Bioequivalence</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study is to evaluate the interchangeability of cefuroxime (&lt;ulink linkType="Drug" linkID="44368"&gt;Zinnat&lt;/ulink&gt;) by GlaxoSmithkline (GSK) Mexico versus cefuroxime  by Weser Pharma, oral suspension at a dose of 250 mg in 5 ml,  in healthy volunteers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study healthy volunteers will recieve  a  dose of 250 mg in 5 ml, of  GSK cefuroxime or cefuroxime of  Weser Pharma.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Mexico"><Sites><Site><Name>Clinical Unit of Bioequivalence</Name><Address1>Guadalajara</Address1><Address2>Jalisco</Address2><CountrySubDivision>Jalisco</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Urinary tract infection</Disease><PatientSegments><PatientSegment><PatientSegment id="11924">Others</PatientSegment><SubSegments><SubSegment id="11925">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Sepsis</Disease><PatientSegments><PatientSegment><PatientSegment id="11918">Others</PatientSegment><SubSegments><SubSegment id="10583">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Bacterial skin infection</Disease><PatientSegments><PatientSegment><PatientSegment id="11887">Others</PatientSegment><SubSegments><SubSegment id="11836">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Otitis media</Disease><PatientSegments><PatientSegment><PatientSegment id="11916">Others</PatientSegment><SubSegments><SubSegment id="10563">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Staphylococcus aureus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="15321">Others</PatientSegment><SubSegments><SubSegment id="18793">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Escherichia coli infection</Disease><PatientSegments><PatientSegment><PatientSegment id="15247">Others</PatientSegment><SubSegments><SubSegment id="11815">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1033">Federal Commission for Protection against Health Risks (COFEPRIS) Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Urinary tract infection" id="14184"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Otitis media" id="14445"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Bacterial skin infection" id="14766"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Sepsis" id="16037"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Escherichia coli infection" id="25824"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Staphylococcus aureus infection" id="33150"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Bacterial skin infection" id="34707"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Bacterial skin infection" id="13758">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Escherichia coli infection" id="34718"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Escherichia coli infection" id="22057">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Otitis media" id="34744"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Otitis media" id="13565">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Sepsis" id="34752"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Sepsis" id="15025">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Urinary tract infection" id="34757"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Urinary tract infection" id="13480">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>